机译:患者报告的健康相关的生活质量来自III阶段的胰岛素碱-MM1研究IXAZOMIB-Lenalaldomide-DexameLisone与Ruppbo-lenalidomide-Dexamethasone的复发/难治性多发性骨髓瘤
Department of HaematologyHospital La Milétrie and INSERM CIC 1402Poitiers France;
Department of Hematology and Stem Cell Transplantation St. István and St. László Hospital 3rd;
Southern Alberta Cancer Research Institute University of CalgaryCalgary Alberta Canada;
Servi?o de Onco‐Hematologia Instituto Português de Oncologia do Porto Francisco Gentil Entidade P;
Department of HaematologyPalmerston North HospitalPalmerston North Manawatu New Zealand;
Department of HematologyUniversity Hospital RigshospitaletCopenhagen Denmark;
4 th Department of Medicine ‐ Hematology University HospitalHradec;
Nizhnii Novgorod Region Clinical HospitalNizhnii Novgorod Russia;
Department of HematologyUniversity of BarcelonaBarcelona Spain;
Department of Internal Medicine IIIUniversity Hospital of UlmUlm Germany;
Division of HematologyUniversity of British ColumbiaVancouver Canada;
Department of HematologyTochigi Cancer Center UtsunomiyaTochigi Japan;
Department of Symptom ResearchUniversity of Texas M.D. Anderson Cancer CenterHouston Texas;
Millennium Pharmaceuticals Inc. Cambridge Massachusetts a wholly owned subsidiary of Takeda;
Millennium Pharmaceuticals Inc. Cambridge Massachusetts a wholly owned subsidiary of Takeda;
Millennium Pharmaceuticals Inc. Cambridge Massachusetts a wholly owned subsidiary of Takeda;
Millennium Pharmaceuticals Inc. Cambridge Massachusetts a wholly owned subsidiary of Takeda;
Department of HematologyUniversity Hospital H?tel DieuNantes France;
Department of Hematologic OncologyDana‐Farber Cancer InstituteBoston Massachusetts;
机译:患者报告的健康相关的生活质量来自III阶段的胰岛素碱-MM1研究IXAZOMIB-Lenalaldomide-DexameLisone与Ruppbo-lenalidomide-Dexamethasone的复发/难治性多发性骨髓瘤
机译:较高的c-MYC表达与依沙米单抗-来那度胺-地塞米松(IRd)无进展生存期(PFS)相对于安慰剂-Rd的关联:电气石-MM1期3期研究在复发/难治性多发性骨髓瘤(RRMM)中的生物标志物分析
机译:较高的c-MYC表达与依沙米单抗-来那度胺-地塞米松(IRd)无进展生存期(PFS)相对于安慰剂-Rd的关联:电气石-MM1期3期研究在复发/难治性多发性骨髓瘤(RRMM)中的生物标志物分析
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:在TOURMALINE-MM1复发/难治性多发性骨髓瘤患者中既往治疗对口服艾达唑仑-来那度胺-地塞米松与安慰剂-来那度胺-地塞米松的疗效和安全性的影响
机译:先前疗法对口服伊沙唑嘧啶 - 来那度胺 - 地塞米松与安慰剂 - 来那度胺 - 地塞米松治疗TOURmaLINE-mm1复发/难治性多发性骨髓瘤疗效和安全性的影响